Thu, May 24, 2012
U.S. panel split on Pfizer rare disease drug
(Reuters) - A U.S. health advisory panel on Thursday issued a split vote on data for Pfizer Inc's drug to treat a rare ...
Thu, May 24, 2012
Mylan settles patent suit over Sunovion's lung drug
(Reuters) - U.S. generic drug maker Mylan Inc settled a patent infringement suit with Sunovion Pharmaceuticals Inc, a unit of Dainippon Sumitomo Pharma Co ...
Thu, May 24, 2012
U.S. Senate passes bipartisan FDA funding bill
By Anna Yukhananov
WASHINGTON (Reuters) - The U.S. Senate on Thursday showed near-unanimous support for a bill that helps fund the U.S. Food ...
Thu, May 24, 2012
Theravance licenses antibiotic tech to Hospira
(Reuters) - Biopharmaceutical company Theravance Inc said it licensed its technology to manufacture antibiotic Vibativ to specialty medicines maker Hospira Inc.
The company would purchase ...
Thu, May 24, 2012
Screening finds skin cancer, but does it save lives?
By Andrew M. Seaman
NEW YORK (Reuters Health) - Doctors find a high number of malignant tumors when a state-wide skin cancer screening program is ...
Thu, May 24, 2012
Anti-obesity proposal fails again at McDonald's
By Lisa Baertlein
OAK BROOK, Ill., May 24 - McDonald's Corp investors soundly rejected a shareholder proposal that would have required the world's ...
Thu, May 24, 2012
Soy supplement shows no blood pressure benefit
By Amy Norton
NEW YORK (Reuters Health) - Soy-rich diets have been linked to lower rates of heart disease, but a small study suggests that ...
Thu, May 24, 2012
Feigning injury could risk lives, says referee
By Mike Collett
BUDAPEST (Reuters) - Howard Webb, the referee when Bolton Wanderers midfielder Fabrice Muamba collapsed on the pitch with a cardiac arrest and ...
Thu, May 24, 2012
Muslim leaders enlisted to help stamp out polio
By Stephanie Nebehay
GENEVA (Reuters) - The last three countries where polio is still paralyzing children -- Afghanistan, Pakistan and Nigeria -- said on Thursday that they ...
Thu, May 24, 2012
Novo obesity drug seen with 43 percent chance of approval
COPENHAGEN (Reuters) - Danish group Novo Nordisk's diabetes drug Victoza has a 43 percent chance of being approved as an obesity treatment in the ...
Recent Comments